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Abstract 
Multi-locus sequence typing was used to reveal a high degree of diversity amongst the E. coli isolates 
with AmpC plasmid genes, and a high prevalence of the -32 mutation present. 
  
Cephalosporins are broad-spectrum antibiotics used to treat a wide range of clinical infections. Some 
serious infections, such as sepsis, can be harder to treat and result in higher mortality rates if strains 
are cephalosporin-resistant (de Kraker et al. 2011). The most common cause of cephalosporin 
resistance in Escherichia coli is production of the CTX-M beta-lactamase enzyme (Potz et al. 2006). 
AmpC beta-lactamase hyper-production, however, is another cause in E. coli, with the enzyme 
normally produced constitutively in small amounts (Caroff et al. 2000). Although blaAmpC genes can 
be acquired on plasmids from other species, chromosomal mutations in the ampC promoter region 
are a more common cause of increased enzyme production (Lewis et al. 2015). Mutations at 
positions -42, -32 and -13ins in the ampC promoter region are considered to be key in affecting the 
level of enzyme production (Tracz et al. 2007). 
 
In our previous study (Lewis et al. 2015), >70% of cefpodoxime-resistance, ESBL-negative E. coli 
strains in Gloucestershire had an ampC promoter mutation present. Unusually, the -32 mutation (T 
to A) was the most common (63%); whereas other studies have reported a higher prevalence for the     
-42 mutation (Mulvey et al. 2005; Mammeri et al. 2008; Bogaerts et al. 2010; Jorgensen et al. 2010; 
Alonso et al. 2016). We therefore set out to investigate whether this was also the case in other parts 
of the South West of England. Multi-locus sequence typing (MLST) was used to determine the 
genetic relatedness of E. coli strains with ampC promoter mutations, with a view to identifying the 
presence of potentially dominant clones. 
 
Clinical isolates of E. coli were collected in five laboratories (Dorchester, Gloucester, Swindon, 
Taunton and Truro) in the South West of England over a 3-month period in 2013. Isolates were 
submitted to the study if found to be cefpodoxime-resistant by disc susceptibility testing. On receipt 
in the testing laboratory (Gloucester), the presence of phenotypic ESBL activity was confirmed using 
clavulanic acid synergy discs (Mast Diagnostics, UK). DNA was extracted using a mechanical lysis 
method described previously (Woodford 2010). PCR assays were run on the Smart Cycler II 
instrument, using the Quantifast SYBR Green master-mix kit (Qiagen, UK). AmpC plasmid groups 
were detected using two multiplex PCR assays (CIT/ACC/DHA and FOX/MOX/EBC). Most primers 
(0.2umol/L) were those described previously (Perez-Perez and Hanson 2002), but some were 
updated to include more recently reported plasmids (Lewis 2016). A PCR protocol of 95oC for 5 mins, 
followed by 35 cycles of 95oC for 10s and 60oC for 30s was used, with melting curve analysis at the 
end. A 271bp region of the ampC gene, including the promoter region, was amplified using 
previously published primers (0.1 umol/L) (Caroff et al. 2000) and the same PCR protocol. PCR 
products were sent to an external company (Eurofins Genomics, Germany) for sequencing, using the 
forward amplification primer.  
 
For MLST, seven housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) were amplified 
using the primers (0.15 umol/L) recommended on the E. coli MLST website 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) (Wirth et al. 2006). A PCR protocol of 95oC for 5 mins, 
followed by 30 cycles of 95oC for 30s, 56oC for 30s and 72oC for 30s was used. PCR products were 
sent to an external company (Eurofins Genomics) for purification and sequencing, using the forward 
amplification primer. The allele numbers and sequence type for each isolate was obtained using the 
online database at http://pubmlst.org/ (Jolley and Maiden 2010).  
 
A total of 77 isolates were confirmed as being cefpodoxime-resistant and ESBL-negative. MLST 
profiles were available for all 77 of the isolates, giving a total of 33 different sequence types (Table 
1). ST73 was the most common (n=15), followed by ST12 (n=13) and ST131 (n=9). Over half (53%) of 
all isolates were allocated to one of just four sequence types. There were two new sequence types 
found in the group (ST5016 and ST5023), both of which were novel to the study. 
 
AmpC plasmid genes were detected in 19 of the isolates (15 CIT-type and 4 DHA-type). These 
isolates were allocated to 14 different sequence types (11 of which were as individuals). This 
confirms the findings of others, in which AmpC plasmid strains were found to have a high degree of 
diversity (Naseer et al. 2010). Although ampC mutations were found in 27 different positions in the 
amplified promoter sequence (Table 2), only three (-42, -32, -13ins) are considered to be key in the 
hyper-production of AmpC beta-lactamase (Tracz et al. 2007). The -32 mutation (T to A) was the 
most common key mutation found, present in nearly half (47.4%) of isolates. This mutation was seen 
in isolates mainly assigned to ST73 (n=14) and ST12 (n=12). Although it is possible that these isolates 
represent the presence of two dominant clones of E. coli that have the -32 mutation present, both 
sequence types (ST12 and ST73) are commonly found in strains without detectable resistance 
(Gibreel et al. 2012; Day et al. 2016). Mutations were also present in other parts of the promoter 
region, including the attenuator (+17 to +37). Whilst mutations in the attenuator region can have an 
impact on the level of enzyme production, this has been shown to be lower than that of the three 
key mutations (-42, -32 and -13ins) (Tracz et al. 2007). 
 
The -42 mutation was present in 12% of strains. Other studies have found a higher prevalence for 
this particular mutation (Mulvey et al. 2005; Jorgensen et al. 2010; Mammeri et al. 2010; Alonso et 
al. 2016), with one reporting a prevalence of 100% (Bogaerts et al. 2010). There were two strains 
(SW-007 and TR-032) that were found to have insertions (thymine) at position -20. Although a 
similar mutation has been reported elsewhere (Jorgensen et al. 2010; Alonso et al. 2016), this may 
be the first report of this mutation in isolates from the UK. 
 
In conclusion, this study confirms the presence of ampC-mediated resistance in 91% of cefpodoxime-
resistant, ESBL-negative E. coli isolates from five laboratories in the South West of England. Isolates 
with key chromosomal ampC mutations were more common (67.1%) than those with acquired ampC 
genes (24.7%). The most common ampC mutation known to cause an increase in enzyme production 
was a T to A transition at position -32. MLST revealed not only a high degree of diversity amongst the 
strains with acquired ampC genes, but also a strong association between the -32 mutation and the 
two sequence types (ST12 and ST73). 
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Table 1: MLST Sequence Types for the 77 E. coli isolates 
  Laboratory 
ST No. DO GL SW TA TR 
73 15 0 6 3 3 3 
12 13 0 9 2 2 0 
131 9 2 2 2 2 1 
778 4 2 2 0 0 0 
38 2 2 0 0 0 0 
40 2 0 1 0 0 1 
69 2 2 0 0 0 0 
88 2 1 1 0 0 0 
127 2 0 1 0 1 0 
357 2 0 0 1 1 0 
648 2 1 0 1 0 0 
10 1 0 1 0 0 0 
56 1 0 0 0 1 0 
80 1 0 0 0 0 1 
95 1 0 0 0 1 0 
117 1 1 0 0 0 0 
200 1 0 1 0 0 0 
372 1 1 0 0 0 0 
404 1 0 0 1 0 0 
405 1 1 0 0 0 0 
420 1 0 0 1 0 0 
421 1 0 0 0 1 0 
448 1 1 0 0 0 0 
453 1 0 1 0 0 0 
533 1 0 0 1 0 0 
624 1 1 0 0 0 0 
963 1 0 1 0 0 0 
1423 1 0 0 1 0 0 
1485 1 1 0 0 0 0 
1641 1 1 0 0 0 0 
2175 1 0 1 0 0 0 
5016* 1 0 1 0 0 0 
5023* 1 0 0 0 1 0 
Total 77 17 27 13 13 7 
 
* indicates a new sequence type detected in this study 
DO, Dorchester; GL, Gloucester; SW, Swindon; TA, Taunton; TR, Truro 
  
Table 2: ampC promoter genotype patterns for 76 E. coli isolates 
Genotype No. Number of 
Isolates 
AmpC Plasmids Mutation Positions* 
G1 16  -73, -32, +58, +63 
G2 11  -73, -32 
G3 3  -73, -32, -28 
G4 1  -73, -32, -28, -20ins  
G5 1  -73, -32, +24, +37 
G6 1  -73, -32, -28, +58 
G7 1  -73, -32, -28, -11 
G8 1  -73, -32, +32, +37 
G9 1  -73, -32, +37  
    
G10 7  -82, -42, -18, -1, +58, +81 
G11 1  -82, -42, -18, -1, +21, +58, +81 
G12 1  -82, -42, -18, -1, +33, +58, +81 
    
G13 2  -73, -28, -13ins, +17  
G14 2  -73, -28, -13ins 
G15 1  -73, -13ins, +6 
G16 1  -73, -28, -13ins, +31, +58 
    
G17 2  -73, -28 
G18 1  -73, -28, -20ins, +17, +34 
G19 1  -73, -28, +17  
G20 1  -73, -28, +34, +58 
G21 1  -76, +22, +26, +27, +32, +70, +71 
    
G22 11 10x CIT, 1x DHA +70, +81 
G23 2 2x CIT -82, -18, -1, +58, +81 
G24 1 1x CIT -73, -28,  
G25 1 1x CIT -73, +58, +63 
G26 1 1x CIT -73, -28, +58 
G27 1 1x DHA -73, -28, +17 
G28 1 1x DHA -73, +32, +58, +63 
G29 1 1x DHA +81 
 
The reported sequence of each product was compared against the GenBank entry for E. coli 
NCTC12241 (GenBank Accession AY899338). 
ins: insertion at position -13 or -20 
numbers in bold represent the key promoter mutations described by Tracz et al. (2007). 
* positions are numbered according to the method used by Jaurin et al. (1981) 
 
 
 
